The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Open accessAbstract
Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16% of all breast cancers. Here we show in 104 TNBC cases that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some having only a handful of coding somatic aberrations in a few pathways, whereas others contain hundreds of coding somatic mutations. High-throughput RNA sequencing (RNA-seq) revealed that only approximately 36% of mutations are expressed. Using deep re-sequencing measurements of allelic abundance for 2,414 somatic mutations, we determine for the first time-to our knowledge-in an epithelial tumour subtype, the relative abundance of clonal frequencies among cases representative of the population. We show that TNBCs vary widely in their clonal frequencies at the time of diagnosis, with the basal subtype of TNBC showing more variation than non-basal TNBC. Although p53 (also known as TP53), PIK3CA and PTEN somatic mutations seem to be clonally dominant compared to other genes, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal, cell shape and motility proteins occurred at lower clonal frequencies, suggesting that they occurred later during tumour progression. Taken together, our results show that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is estimated that p53 is mutated in approximately 50% of all cancers with 60% of TNBCs bearing mutations in p53 (14, 15);”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
In the citing paper
“It is estimated that p53 is mutated in approximately 50% of all cancers with 60% of TNBCs bearing mutations in p53 (14, 15);”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
In the citing paper
“Approximately 60% of basal TNBCs bear mutations in p53 (15) and ~90% of mutations in p53 occur in the DNA binding domain.”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citationSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Self-citationGenome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,144
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,003
Fuso, P., Muratore, M., D’Angelo, T., Paris, I., Carbognin, L., Tiberi, G., Pavese, F., Duranti, S., Orlandi, A., Tortora, G., et al. (2022) · Cancers · doi:10.3390/cancers14092161 · Cited by 55
Triple-Negative Breast Cancer: Molecular Particularities Still a Challenge
Varzaru, V. B., Vlad, T., Popescu, R., Vlad, C. S., Moatar, A. E., & Cobec, I. M. (2024) · Diagnostics · doi:10.3390/diagnostics14171875 · Cited by 55
Triple-negative breast cancer: investigating potential molecular therapeutic target
Papa, A., Caruso, D., Tomao, F., Rossi, L., Zaccarelli, E., & Tomao, F. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.970176 · Cited by 54
What are we learning from the cancer genome?
Collisson, E. A., Cho, R. J., & Gray, J. W. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.159 · Cited by 55
Zagorac, I., Fernandez-Gaitero, S., Penning, R., Post, H., Bueno, M. J., Mouron, S. A., Manso, L., Morente, M. M., Alonso, S. R., Serra, V., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05742-z · Cited by 59
Chan, J. J., Tan, T. J., & Dent, R. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919880429 · Cited by 54
The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer
Liu, H., Paddock, M. N., Wang, H., Murphy, C. J., Geck, R. C., Navarro, A. J., Wulf, G. M., Elemento, O., Haucke, V., Cantley, L. C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1262 · Cited by 56
Savage, P., Pacis, A., Kuasne, H., Liu, L., Lai, D., Wan, A., Dankner, M., Martínez, C., Muñoz-Ramos, V., Pilon, V., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1042-x · Cited by 54
Self-citationTian, T., Zhao, Y., Zheng, J., Jin, S., Liu, Z., & Wang, T. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.017 · Cited by 53
Self-citationCirculating tumour cells: insights into tumour heterogeneity
Hayes, D. F., & Paoletti, C. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12047 · Cited by 53
Are acinic cell carcinomas of the breast and salivary glands distinct diseases?
Piscuoglio, S., Hodi, Z., Katabi, N., Guerini‐Rocco, E., Macedo, G. S., Ng, C. K. Y., Edelweiss, M., Mattos‐Arruda, L. D., Wen, H. Y., Rakha, E. A., et al. (2015) · Histopathology · doi:10.1111/his.12673 · Cited by 53
Polarity gene alterations in pure invasive micropapillary carcinomas of the breast
Gruel, N., Benhamo, V., Bhalshankar, J. D., Popova, T. G., Fréneaux, P., Arnould, L., Mariani, O., Stern, M., Raynal, V., Sastre‐Garau, X., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3653 · Cited by 52
Using Multigene Tests to Select Treatment for Early-Stage Breast Cancer
Gonçalves, R., & Bose, R. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0025 · Cited by 54
Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer
Bakrania, A. K., Variya, B. C., & Patel, S. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.023 · Cited by 53
A population genetics perspective on the determinants of intra-tumor heterogeneity
Hu, Z., Sun, R., & Curtis, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.001 · Cited by 54
Self-citationNovel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance
Sridharan, S., Howard, C. M., Tilley, A. M. C., Subramaniyan, B., Tiwari, A. K., Ruch, R. J., & Raman, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01003 · Cited by 54
Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies
Guarneri, V., Dieci, M. V., & Conte, P. (2013) · Drugs · doi:10.1007/s40265-013-0091-6 · Cited by 52
Wong, S. Q., FELLOWES, A. P., Doig, K. M., Ellul, J., Bosma, T. J., Irwin, D. E., Vedururu, R., Tan, A., Weiss, J. M., Chan, K. S., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.80 · Cited by 52
Walsh, E. M., Keane, M., Wink, D. A., Callagy, G. M., & Glynn, S. A. (2016) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2017021307 · Cited by 54
Immunological therapy: A novel thriving area for triple-negative breast cancer treatment
Wang, X., Qi, Y., Kong, X., Zhai, J., Li, Y., Song, Y., Wang, J., Feng, X., & Fang, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.042 · Cited by 53
Wang, Z., Kong, Q., Su, P., Duan, M., Xue, M., Li, X., Tang, J., Gao, Z., Wang, B., Li, Z., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0220-5 · Cited by 52
Bioinformatics for cancer immunology and immunotherapy
Charoentong, P., Angelova, M., Efremova, M., Gallasch, R., Hackl, H., Galon, J., & Trajanoski, Z. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1354-x · Cited by 52
Powell, E., Shao, J., Yuan, Y., Chen, H.-C., Cai, S., Echeverria, G. V., Mistry, N. A., Decker, K. F., Schlosberg, C., Do, K.-A., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0673-9 · Cited by 50
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer
Santarpia, L., Bottai, G., Kelly, C. M., Győrffy, B., Székely, B., & Pusztai, L. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0369 · Cited by 59
The role of cancer stem cells in tumor heterogeneity and resistance to therapy
Konrad, C. V., Murali, R., Varghese, B. A., & Nair, R. (2016) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2016-0079 · Cited by 51
Hölzel, D., Eckel, R., Bauerfeind, I., Baier, B., Beck, T., Braun, M., Ettl, J., Hamann, U., Kiechle, M. B., Mahner, S., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2428-0 · Cited by 52
Liu, R., Vo, T. M., Jain, S., Choi, W., Garcia, E. P., Monckton, E. A., Mackey, J. R., & Godbout, R. (2018) · The Journal of Pathology · doi:10.1002/path.5182 · Cited by 51
Self-citationTumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
Barroso‐Sousa, R., Pacifico, J. P. M., Sammons, S. L., & Tolaney, S. M. (2023) · Cancers · doi:10.3390/cancers15153997 · Cited by 54
Zhang, C., Zheng, M.-W., Li, Y., Lin, X., Huang, M. J., Zhong, L., Li, G., Zhang, R.-J., Lin, W.-T., Jiao, Y., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00270 · Cited by 50
Self-citationParameterizing cell-to-cell regulatory heterogeneities via stochastic transcriptional profiles
Bajikar, S. S., Fuchs, C., Roller, A., Theis, F. J., & Janes, K. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311647111 · Cited by 47
Markiewicz, A., Ahrends, T., Wełnicka-Jaśkiewicz, M., Seroczyńska, B., Skokowski, J., Jaśkiewicz, J., Szade, J., Biernat, W., & Zaczek, A. J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-226 · Cited by 50
High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer
Judes, G., Rifai, K. T., Daures, M., Dubois, L., Bignon, Y., Penault-Llorca, F. M., & Bernard-Gallon, D. J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.001 · Cited by 50
Maguire, S. L., Peck, B., Wai, P. T., Campbell, J., Barker, H. E., Gulati, A., Daley, F. M., Vyse, S., Huang, P. H., Lord, C. J., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4778 · Cited by 49
CRTC 1– MAML 2 fusion in mucoepidermoid carcinoma of the breast
Bean, G. R., Krings, G., Otis, C. N., Solomon, D. A., García, J. J., van Zante, A., Camelo-Piragua, S. I., Ziffle, J. V., & Chen, Y.-Y. (2018) · Histopathology · doi:10.1111/his.13779 · Cited by 50
Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer
Zardavas, D., & Piccart, M. J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e183 · Cited by 49
Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy
Norum, J. H., Andersen, K., & Sørlie, T. (2014) · British journal of surgery · doi:10.1002/bjs.9562 · Cited by 49
Theranostic and Molecular Classification of Breast Cancer
Cornejo, K. M., Kandil, D. H., Khan, A. A., & Cosar, E. F. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0442-ra · Cited by 51
Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools
Martínez-Montiel, N., Anaya-Ruı́z, M., Pérez-Santos, M., & Martínez-Contreras, R. D. (2017) · Genes · doi:10.3390/genes8100217 · Cited by 48
Therapeutic potential of ERK5 targeting in triple negative breast cancer
Ortiz-Ruiz, M. J., Álvarez-Fernández, S., Parrott, T., Zaknoen, S. L., Burrows, F. J., Ocaña, A., Pandiella, A., & Esparı́s-Ogando, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2324 · Cited by 49
Metabotropic Glutamate Receptor-1 Contributes to Progression in Triple Negative Breast Cancer
Banda, M., Speyer, C. L., Semma, S. N., Osuala, K. O., Kounalakis, N., Torres, K. E., Barnard, N., Kim, H. J., Sloane, B. F., Miller, F. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0081126 · Cited by 49
Werner, B., Dingli, D., & Traulsen, A. (2013) · Journal of The Royal Society Interface · doi:10.1098/rsif.2013.0349 · Cited by 49
Austreid, E., Lønning, P. E., & Eikesdal, H. P. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.885952 · Cited by 49
Chang, C.-T., Korivi, M., Huang, H., Thiyagarajan, V., Lin, K., Huang, P.-J., Liu, J.-Y., Hseu, Y., & Yang, H. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.02.019 · Cited by 49
Intratumor Heterogeneity: Novel Approaches for Resolving Genomic Architecture and Clonal Evolution
Gupta, R. G., & Somer, R. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0070 · Cited by 49
Ji, J., Ma, F., Zhang, H., Liu, F., He, J., Li, W., Xie, T., Zhong, D., Zhang, T., Tian, M., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201801738 · Cited by 49
Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer
Chiu, A. M., Mitra, M., Boymoushakian, L., & Coller, H. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-29992-5 · Cited by 50
Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity
Gupta, I., Sareyeldin, R. M., Al‐Hashimi, I., Al-Thawadi, H., Farsi, H. F. A., Vranić, S., & Moustafa, A. A. (2019) · Cancers · doi:10.3390/cancers11030363 · Cited by 50
Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness
Sridharan, S., Robeson, M., Tukaramrao, D. B., Howard, C. M., Subramaniyan, B., Tilley, A. M. C., Tiwari, A. K., & Raman, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01311 · Cited by 49
MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade
Wang, W., Han, D., Cai, Q., Shen, T., Dong, B., Lewis, M. T., Wang, R., Meng, Y., Zhou, W., Yi, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27921-1 · Cited by 48
Voltage imaging reveals the dynamic electrical signatures of human breast cancer cells
Quicke, P., Sun, Y., Arias-García, M., Beykou, M., Acker, C. D., Djamgoz, M. B. A., Bakal, C., & Foust, A. J. (2022) · Communications Biology · doi:10.1038/s42003-022-04077-2 · Cited by 48
Ge, L., Jin, X., Ma, D., Wang, Z.-Y., Liu, C., Zhou, C., Zhao, S., Yu, T., Liu, X., Di, G. H., et al. (2024) · Cell Research · doi:10.1038/s41422-023-00909-w · Cited by 51
Cancer sequencing unravels clonal evolution
Caldas, C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2213 · Cited by 48
Self-citationSingle-Cell Genetic Analysis Using Automated Microfluidics to Resolve Somatic Mosaicism
Szulwach, K. E., Chen, P., Wang, X., Wang, J., Weaver, L. S., Gonzales, M. L., Sun, G., Unger, M., & Ramakrishnan, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135007 · Cited by 47
Serra, V., Vivancos, A. P., Puente, X. S., Felip, E., Silberschmidt, D., Caratù, G., Parra, J.-L., Mattos‐Arruda, L. D., Grueso, J., Hernández‐Losa, J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0132 · Cited by 48
Liang, H., Zheng, Q.-L., Peng, F., Zhang, J., Zhang, T., Liu, W., Guo, M., Robinson, C. L., Chen, S., Chen, X., et al. (2017) · Scientific Reports · doi:10.1038/srep40361 · Cited by 48
Kawazu, M., Kojima, S., Ueno, T., Totoki, Y., Nakamura, H. K., Kunita, A., Qü, W., Yoshimura, J., Soda, M., Yasuda, T., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006853 · Cited by 48
Adamo, B., Ricciardi, G. R. R., Ieni, A., Franchina, T., Fazzari, C., Sanò, M. V., Angelico, G., Caruso, M., Tuccari, G., & Adamo, V. (2017) · Oncotarget · doi:10.18632/oncotarget.20293 · Cited by 48
Sun, X., Zuo, K., Yao, Q., Zhou, S., Shui, R., Xu, X., Bi, R., Yu, B., Cheng, Y., Tu, X., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0589-x · Cited by 48
Comparative characterization of 3D chromatin organization in triple-negative breast cancers
Kim, T., Han, S., Chun, Y., Yang, H.-J., Min, H., Jeon, S. Y., Kim, J., Moon, H., & Lee, D. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00768-2 · Cited by 49
Mutant Allele Tumor Heterogeneity (MATH) and Head and Neck Squamous Cell Carcinoma
Rocco, J. W. (2015) · Head and Neck Pathology · doi:10.1007/s12105-015-0617-1 · Cited by 47
Tripathy, D., Harnden, K. K., Blackwell, K., & Robson, M. E. (2014) · BMC Medicine · doi:10.1186/s12916-014-0140-3 · Cited by 47
Li, S. C., Tachiki, L. M. L., Kabeer, M. H., Dethlefs, B. A., Anthony, M. J., & Loudon, W. G. (2014) · Cancer Cell International · doi:10.1186/s12935-014-0115-7 · Cited by 47
Kaur, H., Mao, S., Shah, S. K., Gorski, D. H., Krawetz, S. A., Sloane, B. F., & Mattingly, R. R. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.13.4 · Cited by 49
Self-citationAuranofin is a potent suppressor of osteosarcoma metastasis
Topkas, E., Cai, N., Cumming, A., Hazar-Rethinam, M. H., Gannon, O. M., Burgess, M. L., Saunders, N. A., & Endo‐Munoz, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5704 · Cited by 46
The mammary stem cell hierarchy: a looking glass into heterogeneous breast cancer landscapes
Sreekumar, A., Roarty, K. P., & Rosen, J. M. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0263 · Cited by 50
Andreasen, S., Tan, Q., Agander, T. K., Šteiner, P., Bjørndal, K., Høgdall, E. V. S., Larsen, S. R., Erentaite, D., Olsen, C. H., Ulhøi, B. P., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0005-y · Cited by 47
Shimoi, T., Hamada, A., Yamagishi, M., Hirai, M., Yoshida, M., Nishikawa, T., Sudo, K., Shimomura, A., Noguchi, E., Yunokawa, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13696 · Cited by 50
Mukhopadhyay, U. K., Oturkar, C. C., Adams, C., Wickramasekera, N. T., Bansal, S., Medisetty, R., Miller, A., Swetzig, W. M., Silwal‐Pandit, L., Børresen‐Dale, A., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz051 · Cited by 47
Thakuri, P. S., Gupta, M., Singh, S. K., Joshi, R., Glasgow, E. F., Lekan, A. A., Agarwal, S., Luker, G. D., & Tavana, H. (2020) · BMC Cancer · doi:10.1186/s12885-019-6479-2 · Cited by 49
Lee, M. M., Chan, B., Wong, W., Qu, Z., Chan, M.-S., Leung, T.-W., Lin, Y.-S., Mok, D. K., Chen, S., & Tai, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00491 · Cited by 47
Integrative Analysis of Cancer-Related Signaling Pathways
Keßler, T., Hache, H., & Wierling, C. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00124 · Cited by 54
Klinke, D. J. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003409 · Cited by 47
mTOR inhibitors in the treatment of breast cancer.
Vinayak, S., & Carlson, R. W. (2013) · PubMed · Cited by 46
Targeted therapy in rare cancers—adopting the orphans
Munoz, J. L., & Kurzrock, R. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.160 · Cited by 46
Nesset, K. A., Perri, A. M., & Mueller, C. R. (2014) · Epigenetics · doi:10.4161/epi.28484 · Cited by 46
Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
Anestis, A., Karamouzis, M. V., Dalagiorgou, G., & Papavassiliou, A. G. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.009 · Cited by 46
Zebrafish as a model to assess cancer heterogeneity, progression and relapse
Blackburn, J. S., & Langenau, D. M. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.015842 · Cited by 52
Yu, Z., Liu, Y., Shen, Y., Wang, M., & Li, A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu346 · Cited by 46
Whole exome sequencing of rare aggressive breast cancer histologies
Dieci, M. V., Smutná, V., Scott, V., Yin, G., Xu, R., Vielh, P. R., Mathieu, M., Vicier, C., Laporte, M., Drusch, F., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3718-y · Cited by 46
Shaver, T. M., Lehmann, B. D., Beeler, J. S., Li, C.-I., Li, Z., Jin, H., Stricker, T. P., Shyr, Y., & Pietenpol, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0058 · Cited by 46
Metabolomics in Breast Cancer: Current Status and Perspectives
Hart, C. D., Tenori, L., Luchinat, C., & Leo, A. D. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22909-6_9 · Cited by 49
New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology
Li, X., Oprea‐Ilies, G., & Krishnamurti, U. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0288-sa · Cited by 46
Chen, L., Jenjaroenpun, P., Pillai, A. M. C., Ivshina, A. V., Ow, G. S., Motakis, E., Zhiqun, T., Tan, T. Z., Lee, S., Rogers, K., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701512114 · Cited by 46
Levva, S., Kotoula, V., Kostopoulos, I. S., Manousou, K., PAPADIMITRIOU, C. A., Papadopoulou, K., Lakis, S., Koukoulias, K., Karavasilis, V., Pentheroudakis, G. E., et al. (2017) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20030 · Cited by 46
Gray, J. W., & Druker, B. J. (2012) · Nature · doi:10.1038/486328a · Cited by 45
A microscopic landscape of the invasive breast cancer genome
Ping, Z., Xia, Y., Shen, T., Parekh, V., Siegal, G. P., Eltoum, I.-E. A., He, J., Chen, D., Deng, M., Xi, R., et al. (2016) · Scientific Reports · doi:10.1038/srep27545 · Cited by 45
Vartuli, R. L., Zhou, H., Zhang, L., Powers, R. K., Klarquist, J. S., Rudra, P., Vincent, M. Y., Ghosh, D., Costello, J. C., Kedl, R. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96784 · Cited by 43
Self-citationWang, J., Browne, L. H., Šlapetová, I., Shang, F., Lee, K., Lynch, J., Beretov, J., Whan, R. M., Graham, P., & Millar, E. K. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-01116-6 · Cited by 47
Ibarra, L. E., Camorani, S., Agnello, L., Pedone, E. M., Pirone, L., Chesta, C. A., Palacios, R. E., Fedele, M., & Cerchia, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030626 · Cited by 44
Wang, X., Bai, H., Zhang, J., Wang, Z., Duan, J., Cai, H., Cao, Z., Lin, Q., Ding, X., Sun, Y., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.276 · Cited by 44
Adapting Clinical Paradigms to the Challenges of Cancer Clonal Evolution
Murugaesu, N., Chew, S. K., & Swanton, C. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.026 · Cited by 42
Bias from removing read duplication in ultra-deep sequencing experiments
Zhou, W., Chen, T., Zhao, H., Eterovic, A. K., Meric‐Bernstam, F., Mills, G. B., & Chen, K. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt771 · Cited by 44
Natural and chemotherapy-induced clonal evolution of tumors
Ibragimova, M. K., Tsyganov, M. M., & Литвяков, Н. В. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917040022 · Cited by 44
Ex-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments
Muraro, M. G., Muenst, S. E., Mele, V., Quagliata, L., Iezzi, G., Tzankov, A., Weber, W. P., Spagnoli, G. C., & Soysal, S. D. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331798 · Cited by 44
Girnius, N., Edwards, Y. J. K., Garlick, D. S., & Davis, R. J. (2018) · eLife · doi:10.7554/elife.36389 · Cited by 45
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Barry, P. A., Vatsiou, A. I., Spiteri, I., Nichol, D., Cresswell, G. D., Acar, A., Trahearn, N., Hrebien, S., García-Murillas, I., Chkhaidze, K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3374 · Cited by 43
Copy number variation in triple negative breast cancer samples associated with lymph node metastasis
Pariyar, M., Johns, A., Thorne, R. F., Scott, R. J., & Avery‐Kiejda, K. A. (2021) · Neoplasia · doi:10.1016/j.neo.2021.05.016 · Cited by 44
Impact of TP53 mutations in Triple Negative Breast Cancer
Mitri, Z. I., Abuhadra, N. K., Goodyear, S. M., Hobbs, E. A., Kaempf, A. J., Thompson, A. M., & Moulder, S. L. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00303-6 · Cited by 48
Genomic Interaction Profiles in Breast Cancer Reveal Altered Chromatin Architecture
Zeitz, M. J., Ay, F., Heidmann, J. D., Lerner, P. L., Noble, W. S., Steelman, B. N., & Hoffman, A. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073974 · Cited by 43
Molecular tests as prognostic factors in breast cancer
van de Vijver, M. J. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1539-0 · Cited by 43
Metadata
- Authors
- Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., Bashashati, A., Prentice, L. M., Khattra, J., Burleigh, A., Yap, D., Bernard, V., McPherson, A., Shumansky, K., Crisan, A., Giuliany, R., Heravi-Moussavi, A., Rosner, J., Lai, D., Birol, I., Varhol, R., Tam, A., Dhalla, N., Zeng, T., Ma, K., Chan, S. K., Griffith, M., Moradian, A., Cheng, S.-W. G., Morin, G. B., Watson, P., Gelmon, K., Chia, S., Chin, S.-F., Curtis, C., Rueda, O. M., Pharoah, P. D., Damaraju, S., Mackey, J., Hoon, K., Harkins, T., Tadigotla, V., Sigaroudinia, M., Gascard, P., Tlsty, T., Costello, J. F., Meyer, I. M., Eaves, C. J., Wasserman, W. W., Jones, S., Huntsman, D., Hirst, M., Caldas, C., Marra, M. A., & Aparicio, S.
- Affiliations
- University of British Columbia (CA)
- Canada's Michael Smith Genome Sciences Centre (CA)
- BC Cancer Agency (CA)
- University of Cambridge (GB)
- University of Southern California (US)
- Cancer Research UK (GB)
- University of Alberta (CA)
- University of California, San Francisco (US)
- Corresponding author
- Shah, Sohrab P.
- Caldas, Carlos
- Marra, Marco A.
- Aparicio, Samuel
- ORCID
- Shah, Sohrab P.
- Roth, Andrew
- Ha, Gavin
- Zhao, Yongjun
- Turashvili, Gulisa
- Ding, Jiarui
- Haffari, Gholamreza
- Bashashati, Ali
- Prentice, Leah M.
- Burleigh, Angela
- Yap, Damian
- McPherson, Andrew
- Crisan, Anamaria
- Rosner, Jamie
- Lai, Daniel
- Varhol, Richard
- Tam, Angela
- Griffith, Malachi
- Moradian, Annie
- Cheng, S.-W. Grace
- Morin, Gregg B.
- Watson, Peter
- Gelmon, Karen
- Chia, Stephen
- Chin, Suet-Feung
- Curtis, Christina
- Rueda, Oscar M.
- Pharoah, Paul D.
- Damaraju, Sambasivarao
- Mackey, John
- Harkins, Timothy
- Gascard, Philippe
- Tlsty, Thea
- Costello, Joseph F.
- Meyer, Irmtraud M.
- Eaves, Connie J.
- Wasserman, Wyeth W.
- Jones, Steven
- Huntsman, David
- Hirst, Martin
- Caldas, Carlos
- Marra, Marco A.
- Aparicio, Samuel
- Venue
- Nature
- Published
- 2012-04-04
- Volume
- 486
- Issue
- 7403
- Pages
- 395-399
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3863681
- OpenAlex
- W2063382533
- Cited by
- 1,967
- References
- 23
- Citations by year
- 2026: 40 · 2025: 61 · 2024: 71 · 2023: 131 · 2022: 132 · 2021: 119 · 2020: 131 · 2019: 120 · 2018: 135 · 2017: 173 · 2016: 179 · 2015: 198 · 2014: 199 · 2013: 201 · 2012: 76
- FWCI
- 71.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Funders
- U.S. Department of Defense
- Memorial Sloan-Kettering Cancer Center
- Canada's Michael Smith Genome Sciences Centre
- Canadian Breast Cancer Research Alliance
- Michael Smith Health Research BC
- Cancer Research UK
- National Institute for Health and Care Research (NF-SI-0611-10154)
- Cure Brain Cancer Foundation
- BC Cancer Foundation
- National Institutes of Health
- Imperial Experimental Cancer Medicine Centre
- BC Cancer Agency
- National Institute of General Medical Sciences (R01GM084875)
- National Institute of Environmental Health Sciences (U01ES017154)
- Congressionally Directed Medical Research Programs
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- triple-negative breast cancer, clonal evolution, somatic mutations, copy number variation, cancer genomics, TP53 mutation, PIK3CA mutation, PTEN mutation, basal subtype, tumor progression, founder mutation, clonal heterogeneity
- MeSH terms
- Alleles, Breast Neoplasms, Clone Cells, DNA Mutational Analysis, Female, Genotype, Humans, Mutation, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Point Mutation, Sequence Analysis, RNA, Disease Progression, Evolution, Molecular, Gene Expression Profiling, INDEL Mutation, DNA Copy Number Variations, Precision Medicine, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
